{"id":"meningococcal-acyw135-polysaccharide-conjugate-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain/erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses polysaccharide capsules from four meningococcal serogroups conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these serogroups.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135 by presenting conjugated polysaccharide antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:43.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135"}]},"trialDetails":[{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT06389513","phase":"PHASE4","title":"Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-06-12","conditions":"Epidemic Meningitis","enrollment":3011},{"nctId":"NCT06700148","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-14","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06226714","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-01","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06011200","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-16","conditions":"Epidemic Meningitis","enrollment":1000},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT06337071","phase":"PHASE2","title":"A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1200},{"nctId":"NCT05229536","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-12-21","conditions":"Meningitis, Meningococcal","enrollment":720},{"nctId":"NCT02878291","phase":"PHASE1","title":"Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2016-06","conditions":"Meningitis, Meningococcal","enrollment":200},{"nctId":"NCT02003495","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2013-10","conditions":"Meningitis","enrollment":2195},{"nctId":"NCT00901940","phase":"PHASE3","title":"Understanding the Immune Response to Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-06","conditions":"Meningitis, Septicemia","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Menwaycon"],"phase":"phase_3","status":"active","brandName":"Meningococcal ACYW135 Polysaccharide Conjugate Vaccine","genericName":"Meningococcal ACYW135 Polysaccharide Conjugate Vaccine","companyName":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","companyId":"beijing-zhifei-lvzhu-biopharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135 by presenting conjugated polysaccharide antigens. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}